BioSpace News Archive

BriaCell Therapeutics Corp. announces initiation of a first-in-human, Phase 1/2 study evaluating safety and efficacy of Bria-OTS™.

BioSig Technologies, Inc. today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,570,683 shares of its common stock at a purchase price of $1.91 per share in a registered direct offering priced at-the-market under Nasdaq rules.

Candel Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-3110, a next generation oncolytic viral immunotherapy, for the treatment of recurrent high-grade glioma (rHGG). Glioblastoma (GBM) is the most common and aggressive form of high-grade glioma.

Lykos Therapeutics announced the appointment of finance veteran Scott Giacobello to the company’s Board of Directors, effective immediately.

Parse Biosciences today announced the availability of Trailmaker™, its user-friendly cloud platform purpose-built for single cell data analysis.

Science Applications International Corp. announced the launch of Tenjin GPT, a new internal, generative Artificial Intelligence resource available to employees that harnesses cutting-edge AI capabilities to automate and optimize business processes.

Natera, Inc. today announced that the company will present new data on its Prospera donor-derived cfDNA (dd-cfDNA) test at the American Transplant Congress (ATC) 2024 taking place June 1–5, 2024.

Inozyme Pharma, Inc. today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 from 12:30-12:55 pm ET.

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps as a potential treatment for age-related conditions, announced the commencement of several significant milestones.

Genprex, Inc. , today announced that its President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, will be providing an overview of the Company’s gene therapies for cancer and diabetes at the upcoming 2024 BIO International Convention.